Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cabio Biotech (Wuhan) CoSHSE:688089 +0.60%75 PS Ratio is 4.42 as of Aug. 31, 2026, which is 45% below its 10-year median of 8.02. GuruFocus rates SHSE:688089 with a GF Score™ of 75/100 and a GF Value™ of ¥12.10 (Possible Value Trap). The stock has 9 warning signs investors should review. Among 934 Biotechnology companies, Cabio Biotech (Wuhan) Co ranks better than 70.24% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Cabio Biotech (Wuhan) Co's share price is ¥8.36.
Cabio Biotech (Wuhan) Co's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was ¥1.89. Hence, Cabio Biotech (Wuhan) Co's PS Ratio for today is 4.42.
The historical rank and industry rank for Cabio Biotech (Wuhan) Co's PS Ratio or its related term are showing as below:
SHSE:688089'
s PS Ratio Range Over the Past 10 Years
Min: 3.81 Med: 8.02 Max: 23.84
Current: 4.42
During the past 13 years, Cabio Biotech (Wuhan) Co's highest PS Ratio was 23.84. The lowest was 3.81. And the median was 8.02.
SHSE:688089's PS Ratio is ranked better than 70.24% of 934
companies
in the Biotechnology industry
Industry Median: 9.52
vs SHSE:688089: 4.42
Cabio Biotech (Wuhan) Co Ltd revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Cabio Biotech (Wuhan) Co was -47.30% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 9.60% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 12.70% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 8.10% per year.
During the past 13 years, Cabio Biotech (Wuhan) Co's highest 3-Year average Revenue per Share Growth Rate was 18.00% per year. The lowest was -2.80% per year. And the median was 9.60% per year.
Cabio Biotech (Wuhan) Co (SHSE:688089) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688089 vs VRTX, REGN, MRNA: PS Ratio Comparison
For the Biotechnology subindustry, Cabio Biotech (Wuhan) Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cabio Biotech (Wuhan) Co PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cabio Biotech (Wuhan) Co's PS Ratio distribution charts can be found below:
* The bar in red indicates where Cabio Biotech (Wuhan) Co's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Cabio Biotech (Wuhan) Co's Share Price of today is ¥8.36. Cabio Biotech (Wuhan) Co's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1.89.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Cabio Biotech (Wuhan) Co (SHSE:688089) has a PS Ratio of 4.42 as of Aug. 31, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Cabio Biotech (Wuhan) Co and its competitors. This is 45% below median its historical median of 8.02. Over the past decade, Cabio Biotech (Wuhan) Co's PS Ratio has ranged from 3.81 to 23.84. According to the industry distribution chart, Cabio Biotech (Wuhan) Co ranks #278 out of 934 companies in the Biotechnology industry, placing it in the top 29.8%.
Is Cabio Biotech (Wuhan) Co's PS Ratio too high?
Cabio Biotech (Wuhan) Co's current PS Ratio of 4.42 is 45% below median its 10-year median of 8.02. Over the past 10 years, this metric has ranged from a low of 3.81 to a high of 23.84. The Biotechnology industry median PS Ratio is 9.52. Cabio Biotech (Wuhan) Co's value of 4.42 is 53.6% below this industry median. Based on the distribution chart, Cabio Biotech (Wuhan) Co ranks #278 out of 934 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Cabio Biotech (Wuhan) Co has a GF Score™ of 75/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cabio Biotech (Wuhan) Co's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cabio Biotech (Wuhan) Co ranks #278 out of 934 companies for PS Ratio. This puts Cabio Biotech (Wuhan) Co in the upper half of its industry. The industry median PS Ratio is 9.52. Cabio Biotech (Wuhan) Co's value of 4.42 is 53.6% below this benchmark. Historically, Cabio Biotech (Wuhan) Co's own PS Ratio has ranged from 3.81 to 23.84 over the past decade. While the company's 10-year median is 8.02 vs. the industry median of 9.52, Cabio Biotech (Wuhan) Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.52, based on 934 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cabio Biotech (Wuhan) Co's current PS Ratio of 4.42 is 53.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Cabio Biotech (Wuhan) Co and its competitors. For the Biotechnology industry, the median PS Ratio is 9.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cabio Biotech (Wuhan) Co's current PS Ratio is 4.42, which is 45% below median its own 10-year median of 8.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cabio Biotech (Wuhan) Co stock overvalued right now?
Based on GuruFocus' analysis, Cabio Biotech (Wuhan) Co (SHSE:688089) is currently considered Possible Value Trap. The stock's GF Value™ is ¥12.10, compared to a current price of ¥8.36 — trading 30.9% below its estimated fair value. The current PS Ratio is 4.42, which is 45% below median its 10-year median of 8.02 and 53.6% below the Biotechnology industry median of 9.52. Cabio Biotech (Wuhan) Co's overall GF Score™ is 75/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Cabio Biotech (Wuhan) Co (SHSE:688089), the current PS Ratio is 4.42 as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cabio Biotech (Wuhan) Co (SHSE:688089) Overvalued in 2026?
Based on GuruFocus' analysis, Cabio Biotech (Wuhan) Co stock appears to be undervalued.
The current stock price of ¥8.36 is trading 30.9% below its estimated GF Value™ of ¥12.10.
GuruFocus considers Cabio Biotech (Wuhan) Co to be Possible Value Trap.
Key valuation signals for SHSE:688089:
PS Ratio: 4.42 (45% below median its 10-year median of 8.02)
GF Value™: ¥12.10 vs. price of ¥8.36 (30.9% below fair value)
Industry Position: 53.6% below the Biotechnology median (#278 of 934)
No single metric tells the full story. See the SHSE:688089 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cabio Biotech (Wuhan) Co Ltd is a biotechnology company, engaged in Research & Development, production and sales of polyunsaturated fatty acids ARA, algae oil DHA and SA, natural B-carotene and other series products. The products are used in infant formula, dietary nutrition supplements and health Food, special medical formula food and other fields. The company's product sales area covers China, the United States, Europe, Australia, New Zealand, South Korea, and Southeast Asia.
75GF Score
Get the complete analysis for SHSE:688089
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688089 has been successfully added to your 
